To the full analysis
Aurinia Pharmaceuticals stock: growth
AUPHAurinia Pharmaceuticals reported $283.06M in revenue for fiscal 2025, up 20.4% on the prior year, up 41.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
26%
per year from 2006 to 2025, per share 0%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 41.4% | 103.3% | 26.0% |
| Revenue per share | 37.9% | 76.2% | 0.0% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $3.52M | −$22.85M | −$22.25M |
| 2007 | $2.33M | −$33.82M | −$29.33M |
| 2008 | $3.88M | −$15.88M | −$17.73M |
| 2009 | $4.05M | −$7.6M | −$10.69M |
| 2010 | $3.42M | −$3.66M | −$4.42M |
| 2011 | $927.52K | −$2.41M | −$2.51M |
| 2012 | $6.16M | −$9.74M | −$6.59M |
| 2013 | $948.56K | −$2.55M | −$4.63M |
| 2014 | $278K | −$16.65M | −$16.99M |
| 2015 | $235K | −$18.61M | −$17.82M |
| 2016 | $173K | −$23.3M | −$18.74M |
| 2017 | $420K | −$70.79M | −$41.19M |
| 2018 | $463K | −$64.12M | −$51.69M |
| 2019 | $318K | −$88.39M | −$63.69M |
| 2020 | $50.12M | −$102.68M | −$77.2M |
| 2021 | $45.61M | −$180.97M | −$159.19M |
| 2022 | $134.03M | −$108.18M | −$79.82M |
| 2023 | $175.51M | −$78.02M | −$34.18M |
| 2024 | $235.13M | $5.75M | $44.11M |
| 2025 | $283.06M | $287.2M | $135.41M |
Revenue by segment
How Aurinia Pharmaceuticals Inc. makes its money and how that has shifted. Names are as the company reports them.
- Product96%
- License, Collaboration and Royalty Revenue4%
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| Product | $158.53M | $216.19M | $271.35M | 95.9% |
| License, Collaboration and Royalty Revenue | $16.98M | $18.95M | $11.71M | 4.1% |
| Total revenue | $175.51M | $235.13M | $283.06M | 100% |
Revenue by region
Where Aurinia Pharmaceuticals Inc. generates its revenue.
- United States93%
- Japan7%
Figures as a table
| 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|
| United States | $102.46M | $157.96M | $210.1M | $263.84M | 93.2% |
| Japan | $31.48M | $17.56M | $25.04M | $19.21M | 6.8% |
| Total revenue | $134.03M | $175.51M | $235.13M | $283.06M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 12 Nov 2026, previously Strong
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.